Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- JGA Prepares Tools for Education of MRs from Its Member Companies
March 2, 2009
- REGULATORY NEWS IN BRIEF
March 2, 2009
- MEDICAL DEVICE NEWS IN BRIEF
March 2, 2009
- Bayer Yakuhin: Wellnara for Postmenopausal Osteoporosis
March 2, 2009
- Skirmishes Heat Up between Pro- and Anti-Online Drug Sale Camps
March 2, 2009
- Project Begun in Order to Verify Usefulness of MD Studies
March 2, 2009
- Group of LDP Lawmakers to Draft Bill to Restrict Online Sale of OTC Drugs
March 2, 2009
- Shionogi's Velneperit Meets Primary Endpoint in 2 PIIb Trials
March 2, 2009
- Gov't to Issue Action Program and GL for New-Type Influenza
March 2, 2009
- R&D NEWS IN BRIEF
March 2, 2009
- Tamiflu-Resistant Influenza Virus Spreading in Japan
March 2, 2009
- National Cancer Center Posts Generics It Uses on Its Website
March 2, 2009
- No Causal Relation between Tamiflu and Abnormal Behavior: WG on Basic Studies
March 2, 2009
- HPV Vaccination Should Be Provided at Government Expense
March 2, 2009
- Sanofi-aventis Seeks Top-Five Place in Japan
March 2, 2009
- Training Courses on CKD Planned for Healthcare Providers
March 2, 2009
- Eisai Licenses Zebinix for Epilepsy from Bial-Portela
March 2, 2009
- TOPICS 2 articles
March 2, 2009
- MEDICAL DEVICE NEWS IN BRIEF
February 23, 2009
- Olmetec Goes to Front on Both GP and HP Markets: Rep Track Survey
February 23, 2009
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…